Besponsa (Inotuzumab Ozogamicin) Approved for Deadly Blood Cancer

THURSDAY, Aug. 17, 2017 -- The U.S. Food and Drug Adminstration on Thursday approved the anti-cancer drug Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia (ALL). B-cell ALL is a rapidly growing cancer that occurs when...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news